XML 16 R1.htm IDEA: XBRL DOCUMENT

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Jun. 30, 2021	Aug. 20, 2021	Dec. 31, 2020
Cover [Abstract]
Entity Registrant Name	Electromed, Inc.
Entity Central Index Key	0001488917
Document Type	10-K
Document Period End Date	Jun. 30, 2021
Amendment Flag	false
Entity File Number	001-34839
Entity Incorporation, State Code	MN
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Smaller Reporting Company	true
Entity Shell Company	false
Entity Public Float			$ 70,780,000
Entity Common Stock, Shares Outstanding		8,588,590
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021

XML 17 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Current Assets
Cash and cash equivalents	$ 11,889,000	$ 10,479,000
Accounts receivable (net of allowances for doubtful accounts of $45,000)	17,032,000	12,941,000
Contract assets	393,000	903,000
Inventories	2,114,000	3,085,000
Prepaid expenses and other current assets	276,000	353,000
Income tax receivable		262,000
Total current assets	31,704,000	28,023,000
Property and equipment, net	3,605,000	3,788,000
Finite-life intangible assets, net	663,000	598,000
Other assets	88,000	81,000
Deferred income taxes	1,049,000	755,000
Total assets	37,109,000	33,245,000
Current Liabilities
Current maturities of other long-term liabilities	33,000	72,000
Accounts payable	685,000	556,000
Accrued compensation	2,474,000	1,404,000
Income tax payable	288,000
Warranty reserve	940,000	740,000
Other accrued liabilities	219,000	214,000
Total current liabilities	4,639,000	2,986,000
Other long-term liabilities	54,000	9,000
Total liabilities	4,693,000	2,995,000
Commitments and Contingencies
Shareholders' Equity
Common stock, $0.01 par value, 13,000,000 shares authorized; 8,533,209 and 8,567,834 issued and outstanding, as of June 30, 2021 and June 30, 2020, respectively	85,000	86,000
Additional paid-in capital	17,409,000	16,480,000
Retained earnings	14,922,000	13,684,000
Total shareholders' equity	32,416,000	30,250,000
Total liabilities and shareholders' equity	$ 37,109,000	$ 33,245,000

XML 18 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 45,000	$ 45,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	13,000,000	13,000,000
Common stock, issued	8,533,209	8,567,834
Common stock, outstanding	8,533,209	8,567,834

XML 19 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Net revenues	$ 35,756,000	$ 32,471,000
Cost of revenues	8,451,000	7,271,000
Gross profit	27,305,000	25,200,000
Operating expenses (income)
Selling, general and administrative	22,443,000	19,945,000
Research and development	1,722,000	1,050,000
Government stimulus income		(913,000)
Total operating expenses	24,165,000	20,082,000
Operating income	3,140,000	5,118,000
Interest income, net	39,000	121,000
Other expense, net	(12,000)	0
Net income before income taxes	3,167,000	5,239,000
Income tax expense	805,000	1,078,000
Net income	$ 2,362,000	$ 4,161,000
Income per share:
Basic (in dollars per share)	$ 0.28	$ 0.5
Diluted (in dollars per share)	$ 0.27	$ 0.47
Weighted-average common shares outstanding:
Basic (in shares)	8,566,224	8,403,220
Diluted (in shares)	8,911,842	8,826,418

XML 20 R5.htm IDEA: XBRL DOCUMENT

Statements of Shareholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at beginning at Jun. 30, 2019	$ 84,000	$ 16,128,000	$ 9,523,000	$ 25,735,000
Balance at beginning (in shares) at Jun. 30, 2019	8,408,351
Increase (Decrease) in Stockholders' Equity
Net income			4,161,000	4,161,000
Issuance of restricted stock	$ 1,000	(1,000)
Issuance of restricted stock (in shares)	50,000
Issuance of common stock upon exercise of options	$ 1,000	79,000		80,000
Issuance of common stock upon exercise of options (in shares)	109,483
Taxes paid on stock option exercised on a net basis		(628,000)		(628,000)
Share-based compensation expense		902,000		902,000
Balance at ending at Jun. 30, 2020	$ 86,000	16,480,000	13,684,000	$ 30,250,000
Balance at ending (in shares) at Jun. 30, 2020	8,567,834			8,567,834
Increase (Decrease) in Stockholders' Equity
Net income			2,362,000	$ 2,362,000
Issuance of restricted stock (in shares)	37,090
Issuance of common stock upon exercise of options		46,000		46,000
Issuance of common stock upon exercise of options (in shares)	32,496
Taxes paid on stock option exercised on a net basis		(141,000)		(141,000)
Share-based compensation expense		1,024,000		1,024,000
Repurchase of common stock	$ (1,000)		(1,123,000)	$ (1,124,000)
Repurchase of common stock (in shares)	(104,211)			(104,211)
Balance at ending at Jun. 30, 2021	$ 85,000	$ 17,409,000	$ 14,922,000	$ 32,416,000
Balance at ending (in shares) at Jun. 30, 2021	8,533,209			8,533,209

XML 21 R6.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Cash Flows From Operating Activities
Net income	$ 2,362,000	$ 4,161,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	477,000	619,000
Amortization of finite-life intangible assets	133,000	122,000
Share-based compensation expense	1,024,000	902,000
Deferred income taxes	(294,000)	(126,000)
Changes in operating assets and liabilities:
Accounts receivable	(4,091,000)	(181,000)
Contract assets	510,000	93,000
Inventories	971,000	(449,000)
Prepaid expenses and other assets	151,000	78,000
Income tax receivable	262,000	(262,000)
Income tax payable	288,000	(289,000)
Accounts payable and accrued liabilities	1,284,000	(472,000)
Net cash provided by operating activities	3,077,000	4,196,000
Cash Flows From Investing Activities
Expenditures for property and equipment	(287,000)	(844,000)
Expenditures for finite-life intangible assets	(161,000)	(133,000)
Net cash used in investing activities	(448,000)	(977,000)
Cash Flows From Financing Activities
Taxes paid on stock options exercised on a net basis	(141,000)	(628,000)
Issuance of common stock upon exercise of options	46,000	80,000
Repurchase of common stock	(1,124,000)
Net cash used in financing activities	(1,219,000)	(548,000)
Net increase in cash	1,410,000	2,671,000
Cash and cash equivalents
Beginning of period	10,479,000	7,808,000
End of period	11,889,000	10,479,000
Supplemental Disclosures of Cash Flow Information
Cash paid for income taxes	534,000	1,755,000
Supplemental Disclosures of Noncash Investing and Financing Activities
Property and equipment acquisitions in accounts payable	10,000	1,000
Intangible asset acquisitions in accounts payable	42,000	6,000
Lease assets obtained in exchange for new operating lease liabilities	$ 91,000	$ 120,000

XML 22 R7.htm IDEA: XBRL DOCUMENT

Nature of Business and Summary of Significant Accounting Policies

12 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Nature of Business and Summary of Significant Accounting Policies

Note 1. Nature of Business and Summary of Significant Accounting Policies

Nature of business: Electromed, Inc. (the “Company”) develops, manufactures and markets innovative airway clearance products that apply High Frequency Chest Wall Oscillation (“HFCWO”) therapy in pulmonary care for patients of all ages. The Company markets its products in the U.S. to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also sells internationally both directly and through distributors. International sales were approximately $658,000 and $718,000 for the fiscal years ended June 30, 2021 (“fiscal 2021 and June 30, 2020 (“fiscal 2020”), respectively. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment.

A summary of the Company’s significant accounting policies follows:

Use of estimates: Management uses estimates and assumptions in preparing the financial statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its financial statements include revenue recognition and the related estimation of variable consideration, allowance for doubtful accounts, the potential impairment of intangible and long-lived assets, inventory obsolescence, share-based compensation and the warranty reserve.

COVID-19 Pandemic and CARES Act Funding

The Company did not receive any direct financial assistance from any government program during fiscal 2021. The Company received a one-time $913,000 payment under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) in the fourth quarter of fiscal 2020, which partially offset lower profitability related to the revenue decline caused by the COVID-19 pandemic during the period. The amount received from the CARES Act is subject to compliance with certain terms and conditions and reporting requirements, and such report may be audited by a federal agency for compliance with the program’s terms and conditions.

In response to the COVID-19 pandemic and the U.S. federal government’s declaration of a public health emergency, the Centers for Medicare and Medicaid Services implemented a number of temporary rule changes and waivers to allow prescribers to best treat patients during the period of the public health emergency. These waivers were made retroactively effective to March 1, 2020 and were in place for the duration of fiscal 2021. Clinical indications and documentation typically required were not enforced for respiratory related products including the Company’s SmartVest® Airway Clearance System (“SmartVest System”) (solely with respect to direct Medicare covered patients) applicable for the Company’s home care prescriptions. The minimum documentation now requires a valid order and documentation of a respiratory related diagnosis. Face-to-face and in-person requirements for replacement respiratory devices are being waived during such period, both of which are currently scheduled to expire in October 2021. A temporary suspension of a 2% tax on Medicare payments was also initiated in May 2020 and has been extended through December 2021.

The impact of the COVID-19 pandemic on the Company’s business remains uncertain and its effects on operational and financial performance will depend in part on future developments, which cannot be reasonably estimated at this time. Such future developments include, but are not limited to, the duration, scope and severity of the COVID-19 pandemic in geographic areas in which the Company operates or in which its patients live, actions taken to contain or mitigate its impact, the impact on governmental healthcare programs and budgets, the deployment of treatments or vaccines, and the resumption of widespread economic activity. Due to the inherent uncertainty of the unprecedented and evolving situation, the Company is unable to predict with confidence the likely impact of the COVID-19 pandemic on its future operations.

Revenue recognition: Revenue is measured based on consideration specified in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, including noncash consideration, consideration paid or payable to customers and significant financing components. Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. See Note 2 for information on revenue.

Shipping and handling expense: Shipping and handling charges incurred by the Company are included in cost of revenues and were $530,000 and $515,000 for fiscal 2021 and 2020, respectively.

Cash and cash equivalents: Cash and cash equivalents consist of cash in bank deposits and money market funds with original maturities of three months or less at the time of purchase. The Company has not experienced any losses in these accounts.

Accounts receivable: The Company’s accounts receivable balance is comprised of amounts due from individuals, institutions and distributors. Balances due from individuals are typically remitted to the Company by third-party reimbursement agencies such as Medicare, Medicaid and private insurance companies. Accounts receivable are carried at amounts estimated to be received from patients under reimbursement arrangements with third-party payers. Accounts receivable are also net of an allowance for doubtful accounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition and credit history. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received. The allowance for doubtful accounts was approximately $45,000 as of June 30, 2021 and 2020.

Contract assets: Contract assets include amounts recognized as revenue that are estimates of variable consideration for Medicare appeals where the final determination of the insurance coverage amount is dependent on future approval of an appeal, or when the consideration due to the Company is dependent on a future event such as the patient meeting a deductible prior to the Company’s claim being processed by the payer. Contract assets are classified as current as amounts will turn into accounts receivable and be collected during the Company’s normal business operating cycle. Contract assets are reclassified to accounts receivable when the right to receive payment is unconditional.

Inventories: Inventories are stated at the lower of cost (first-in, first-out method) or net realizable value. Work in process and finished goods are carried at standard cost, which approximates actual cost, and includes materials, labor and allocated overhead. Standard costs are reviewed at least quarterly by management, or more often in the event circumstances indicate a change in cost has occurred. The reserve for obsolescence is determined by analyzing the inventory on hand and comparing it to expected future sales. Estimated inventory to be returned is based on how many devices that have shipped that are expected to be returned prior to completion of the insurance reimbursement process.

Property and equipment: Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining lease term. The Company retains ownership of demonstration equipment in the possession of both inside and outside sales representatives, who use the equipment in the sales process.

Finite-life intangible assets: Finite-life intangible assets include patents and trademarks. These intangible assets are amortized on a straight-line basis over their estimated useful lives, as described in Note 5.

Long-lived assets: Long-lived assets, primarily property and equipment and finite-life intangible assets, are evaluated for impairment whenever events or changes in circumstances indicate the carrying value of an asset or asset group may not be recoverable. In evaluating recoverability, the following factors, among others, are considered: a significant change in the circumstances used to determine the amortization period, an adverse change in legal factors or in the business climate, a transition to a new product or service strategy, a significant change in customer base, and a realization of failed marketing efforts. The recoverability of an asset or asset group is measured by a comparison of the carrying value of the asset to future undiscounted cash flows.

If the Company believes the carrying value is unrecoverable, then it recognizes an impairment charge necessary to reduce the unamortized balance to the estimated fair value of the asset or asset group. The amount of such impairment is charged to operations in the current period.

Warranty liability: The Company provides a lifetime warranty on its products to the prescribed patient for sales within the U.S. and Canada, and a three-year warranty for all institutional sales and sales to individuals outside the U.S. (except for Canadian home care). The Company estimates the costs that may be incurred under its warranty and records a liability in the amount of such costs at the time the product is shipped. Factors that affect the Company’s warranty liability include the number of units shipped, historical and anticipated rates of warranty claims, the product’s useful life, and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amounts as necessary.

Changes in the Company’s warranty liability were approximately as follows:

	Years Ended June 30,
	2021			2020
Beginning warranty reserve	$	740,000		$	810,000
Accrual for products sold		354,000			79,000
Expenditures and costs incurred for warranty claims		(154,000	)		(149,000	)
Ending warranty reserve	$	940,000		$	740,000

Income taxes: Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company reverses a valuation allowance if it determines, based on the weight of all available evidence, including when cumulative losses become positive income, that it is more likely than not that some or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

The Company recognizes tax liabilities when the Company believes that certain positions may not be fully sustained upon review by tax authorities. Benefits from tax positions are measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon settlement. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences impact income tax expense in the period in which such determination is made. Interest and penalties, if any, related to accrued liabilities for potential tax assessments are included in income tax expense.

Research and development: Research and development costs include costs of research activities as well as engineering and technical efforts required to develop new products or make improvements to existing products. Research and development costs are expensed as incurred.

Advertising costs: Advertising costs are charged to expense when incurred. Advertising, marketing and trade show costs for fiscal 2021 and 2020 were approximately $1,062,000 and $781,000, respectively.

Share-based payments: Share-based payment awards consist of options to purchase shares of common stock and restricted shares of common stock issued to employees for services. Expense for options is estimated using the Black-Scholes pricing model at the date of grant and expense for restricted stock is determined by the closing price on the day the grant is made. Expense is recognized on a straight-line basis over the requisite service or vesting period of the award, or at the time services are provided for non-employee awards.

Fair value of financial instruments: The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their fair value due to the short-term nature of these instruments. The carrying value of long-term debt is the remaining amount due to debtors under borrowing arrangements. To estimate the fair value of debt, the Company estimates the interest rate necessary to secure financing to replace its debt.

Basic and diluted earnings per share: Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into shares of common stock at the beginning of the period, unless their effect is anti-dilutive. Common stock equivalents of 48,617 and zero shares were excluded from the calculation of diluted earnings per share for fiscal 2021 and 2020, respectively, as their impact was antidilutive. See Note 8 for information on share-based payments.

XML 23 R8.htm IDEA: XBRL DOCUMENT

Revenues

12 Months Ended

Jun. 30, 2021

Revenue from Contract with Customer [Abstract]

Revenues

Note 2. Revenues

Revenue is measured based on consideration specified in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, including non-cash consideration, consideration paid or payable to customers and significant financing components. Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer, as further described below under Performance obligations and transaction price.

Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the individual good or service is distinct (i.e., the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement). If an arrangement includes multiple performance obligations, the consideration is allocated between the performance obligations in proportion to their estimated standalone selling price, unless discounts or variable consideration is attributable to one or more but not all the performance obligations. Costs related to products delivered are recognized in the period incurred, unless criteria for capitalization of costs under Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 340-40, “Other Assets and Deferred Costs” (“ASC 340”), or other applicable guidance are met.

The Company includes shipping and handling fees in net revenues. Shipping and handling costs associated with the shipment of the SmartVest System after control has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues.

The timing of revenue recognition, billings and cash collections results in accounts receivable on the balance sheets as further described below under Accounts receivable and Contract assets.

Disaggregation of revenues. In the following table, revenue is disaggregated by market:

	Fiscal Year Ended June 30,
	2021		2020
Home Care	$	32,986,000	$	29,323,000
Institutional		1,549,000		2,000,000
Home Care Distributor		563,000		430,000
International		658,000		718,000
Total	$	35,756,000	$	32,471,000

In the following table, home care revenue is disaggregated by payer type:

	Fiscal Year Ended June 30,
	2021		2020
Commercial	$	12,530,000	$	11,728,000
Medicare		19,044,000		14,863,000
Medicaid		846,000		1,696,000
Other		566,000		1,036,000
Total	$	32,986,000	$	29,323,000

Revenues in the Company’s home care, home care distributor and international markets are recognized at a point in time when control passes to the customer upon product shipment or delivery. Revenues in the Company’s institutional market include sales recognized at a point in time upon shipment or delivery as well as revenues recognized over time under operating leases.

Performance obligations and transaction price. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under ASC 606, “Revenue From Contracts With Customers” (“ASC 606”). A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s performance obligations and the timing or method of revenue recognition in each of the Company’s markets are discussed below:

Home care market. In the Company’s home care market, its customers are patients who use the SmartVest System. The various models of the SmartVest System are comprised of three main components - a generator, a vest and a connecting hose - that are sold together as an integrated unit. Accordingly, in contracts within the home care market, the Company regards the SmartVest System to be a single performance obligation.

The Company makes available to its home care patients limited post-sale services that are not material in the context of the contracts, either individually or taken together, and therefore does not consider them to be performance obligations.

The costs associated with the services are accrued and expensed when the related revenues are recognized. As such, transactions in the home care market consist of a single performance obligation: the SmartVest System.

Home care patients generally will rely on third-party payers, including commercial payers and governmental payers such as Medicare, Medicaid and the U.S. Department of Veterans Affairs to cover and reimburse all or part of the cost of the SmartVest System. The third-party payers’ reimbursement programs fall into three types, distinguished by the differences in the timing of payments from the payer, consisting of either (i) outright sale, in which payment is received from the payer based on standard terms, (ii) capped installment sale, under which the SmartVest System is sold for a series of payments that are capped not to exceed a prescribed or negotiated amount over a period of time or (iii) installment sale, under which the SmartVest System is paid for over a period of several months as long as the patient continues to use the SmartVest System.

Regardless of the type of transaction, provided criteria for an enforceable contract are met, it is the Company’s long-standing business practice to regard all home care agreements as transferring control to the patient upon shipment or delivery, in spite of possible payment cancellation under government or commercial programs where the payer is controlling the payment over specified time periods. For home care sales that feature installment payments, the ultimate amount of consideration received from Medicare, Medicaid or commercial payers can be significantly less than expected if the contract is terminated due to changes in the patient’s status, including insurance coverage, hospitalization, death or otherwise becoming unable to use the SmartVest System. However, once delivered to a patient who needs the SmartVest System, the patient is under no obligation to return the SmartVest System should payments be terminated as a result of the described contingencies. As a result, the Company’s product sales qualify for point in time revenue recognition. Control transfers to the patient, and revenue is recognized, upon shipment of the SmartVest System. At this point, physical possession and the significant risks and rewards of ownership are transferred to the patient and either a current or future right to payment is triggered, as further discussed under Accounts receivable and Contract assets below.

The Company’s contractually stated transaction prices in the home care market are generally set by the terms of the contracts negotiated with insurance companies or by government programs. The transaction price for the Company’s products may be further impacted by variable consideration. ASC 606 requires the Company to adjust the transaction price at contract inception and throughout the contract duration for the estimated value of payments to be received from insurance payers based on historical experience and other available information, subject to the constraint on estimates of variable consideration. Transactions requiring estimates of variable consideration primarily include (i) capped installment payments, which are subject to the third-party payer’s termination due to changes in insurance coverage, death or the patient’s discontinued use of the SmartVest System, (ii) contracts under appeal and (iii) patient responsibility amounts for deductibles, coinsurance, copays and other similar payments.

Although estimates may be made on a contract-by-contract basis, whenever possible, the Company uses all available information including historical collection patterns to estimate variable consideration for portfolios of contracts. The Company’s estimates of variable consideration consist of amounts it may receive from insurance providers in excess of its initial revenue estimate due to patients meeting deductibles or coinsurance during the payment duration, changes to a patient’s insurance status, changes in an insurance allowable, claims in appeals with Medicare and amounts received directly from patients for their allowable or coinsurance. The Company believes it has representative historical information to estimate the amount of variable consideration in relevant portfolios considering the significant experience it has with each portfolio and the similarity of patient accounts within a portfolio. The analysis includes steps to ensure that revenue recognized on a portfolio basis does not result in a material difference when compared with an individual contract approach. The Company also leverages its historical experience and all available relevant information for each portfolio of contracts to minimize the risk its estimates used to arrive at the transaction price will result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur.

For example, for contracts in which the Company believes the criteria for reimbursement under government or commercial payer contracts have been met but for which coverage is unconfirmed or payments are under appeal, the Company has significant observable evidence of relatively consistent claims recovery experience over the prior three to five years. The Company believes the low volatility in historical claims approval rates for populations of patients whose demographics are similar to those of current patients provides reliable predictive value in arriving at estimates of variable consideration in such contracts. Similarly, historical payment trends for recovery of claims subject to payer installments and payments from patients have remained relatively consistent over the past five years. No significant changes in patient demographics or other relevant factors have occurred that would limit the predictive value of such payment trends in estimating variable consideration for current contracts. As a result, the Company believes its estimates of variable consideration are generally not subject to the risk of significant revenue reversal.

For each type of variable consideration discussed above, there are a large number of contracts with similar characteristics with a wide range of possible transaction prices. For that reason, the Company uses the probability-weighted expected value method provided under ASC 606 to estimate variable consideration.

The Company often receives payment from third-party payers for the SmartVest System sales over a period of time that may exceed one year. Despite these extended payment terms, no significant financing component is deemed to exist because the purpose of such terms is not to provide financing to the patient, the payer or the Company. Rather, the extended payment terms are mandated by the government or commercial insurance programs, the fundamental purpose of which is to avoid paying the full purchase price of equipment that may potentially be used by the patient for only a short period of time.

Home Care Distributors. Sales to distributors, who sell direct to patients, are made at fixed contract prices and may include tiered pricing structures or volume-based rebates which offer more favorable pricing once certain volumes are achieved per the negotiated contract. The distributor’s purchases accumulate to give the distributor a right to a higher discount on purchases in excess of the specified level within the contract period. As a result, to the extent the Company expects the distributor to exceed the specified volume of purchases in the annual period, it recognizes revenue at a blended rate based on estimated total annual volume and sales revenue. This effectively defers a portion of the transaction price on initial purchases below the specified volumes for recognition when the higher discount is earned on purchases in excess of specified volumes. Transfer of control of the products occurs upon shipment or delivery to the distributor as applicable.

Institutional market. The Company’s institutional sales are made to hospitals and home health care centers, pulmonary rehabilitation centers and other clinics. Sales to these institutions are negotiated with the individual institution or with group purchasing organizations, with payments received directly from the institution. No insurance reimbursement is involved. Generators are either sold or leased to the institutions and associated hoses and wraps (used in institutional settings rather than vests) are sold separately. Accordingly, each product is distinct and considered a separate performance obligation in sales to institutional customers. The agreements with institutions fall into two main types, distinguished by differences in the timing of transfer of control and timing of payments:

●

Outright sale – Under these transactions, the Company sells its products for a prescribed or negotiated price. Transfer of control of the product, and associated revenue recognition, occurs at the time of shipment and payment is made within normal credit terms, usually within 30 days.

●

Rentals – Under these transactions, the customer obtains a right to use the product for a period of time in exchange for consideration as usage occurs. These transactions are treated as operating leases and revenue is recognized ratably over the applicable rental period. Lease revenue recognized during fiscal 2021 and 2020 was approximately $1,000 and $6,000, respectively.

International market. Sales to international markets are made directly to a number of independent distributors at fixed contract prices that are not subject to further adjustments for variable consideration. Transfer of control of the products occurs upon shipment or delivery to the distributor as applicable.

Product Warranty. The Company offers warranties on its products. These warranties are assurance type warranties not sold on a standalone basis or are otherwise considered immaterial in the context of the contract, and therefore are not considered distinct performance obligations under ASC 606. The Company estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product is sold. From time to time the Company will provide accessory parts at its discretion at no cost to the customer.

Accounts receivable. Accounts receivable include amounts billed to customers and third-party payers, for which only the passage of time is required before payment of consideration is due. Amounts due are stated at their net estimated realizable value.

Contract assets. Contract assets include amounts recognized as revenue that are estimates of variable consideration for Medicare appeals where the final determination of the insurance coverage amount is dependent on future approval of an appeal, or when the consideration due to the Company is dependent on a future event such as the patient meeting a deductible prior to the Company’s claim being processed by the payer. Contract assets are classified as current as amounts will turn into accounts receivable and be collected during the Company’s normal business operating cycle. Contract assets are reclassified to accounts receivable when the right to receive payment is unconditional.

Incremental costs to obtain a contract. Sales incentives paid to sales representatives are eligible for capitalization as they are incremental costs that would not have been incurred without entering into a specific sales arrangement and are recoverable through the expected margin on the transaction. However, the recovery period is less than one year as the performance obligation is satisfied upon shipment or delivery. Consequently, the Company applies the practical expedient provided by ASC 340 and expense sales incentives as incurred. These costs are included in selling, general and administrative expenses in the Company’s statements of operations.

Contract balances. The following table provides information about accounts receivable and contracts assets from contracts with customers:

	June 30, 2021		June 30, 2020
Receivables, included in “Accounts receivable, net of allowance for doubtful accounts”	$	17,032,000	$	12,941,000
Contract assets	$	393,000	$	903,000

Significant changes in contract assets during the period are as follows:

	Fiscal Year Ended			Fiscal Year Ended
	June 30, 2021			June 30, 2020
	Increase (decrease)			Increase (decrease)
Contract assets, beginning	$	903,000		$	996,000
Reclassification of contract assets to accounts receivable		(1,551,000	)		(1,858,000	)
Contract assets recognized		1,060,000			1,734,000
Increase (decrease) as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period		(19,000	)		31,000
Contract assets, ending	$	393,000		$	903,000

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

XML 24 R9.htm IDEA: XBRL DOCUMENT

Inventories

12 Months Ended

Jun. 30, 2021

Inventory Disclosure [Abstract]

Inventories

Note 3. Inventories

The components of inventories as of June 30, 2021 and 2020 were approximately as follows:

	June 30,
	2021			2020
Parts inventory	$	1,779,000		$	2,271,000
Work in process		23,000			127,000
Finished goods		445,000			827,000
Estimated inventory to be returned		167,000			150,000
Less: Reserve for obsolescence		(300,000	)		(290,000	)
Total	$	2,114,000		$	3,085,000

XML 25 R10.htm IDEA: XBRL DOCUMENT

Property and Equipment

12 Months Ended

Jun. 30, 2021

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 4. Property and Equipment

Property and equipment were approximately as follows:

	Estimated Useful		June 30,
	Lives (Years)		2021			2020
Building and building improvements		15-39	$	3,446,000		$	3,437,000
Land		N/A		200,000			200,000
Land improvements		15		166,000			166,000
Equipment		3-7		3,467,000			3,311,000
Demonstration and rental equipment		3		1,060,000			1,075,000
Construction in progress		N/A		26,000			16,000
				8,365,000			8,205,000
Less: Accumulated depreciation				(4,760,000	)		(4,417,000	)
Net property and equipment			$	3,605,000		$	3,788,000

XML 26 R11.htm IDEA: XBRL DOCUMENT

Finite-life Intangible Assets

12 Months Ended

Jun. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Finite-life Intangible Assets

Note 5. Finite-life Intangible Assets

The carrying value of patents and trademarks includes the original cost of obtaining the patents, periodic renewal fees, and other costs associated with maintaining and defending patent and trademark rights. Patents and trademarks are amortized over their estimated useful lives, generally 15 and 12 years, respectively. Accumulated amortization was approximately $1,248,000 and $1,119,000 as of June 30, 2021 and 2020, respectively.

The activity and net balances of finite-life intangible assets were approximately as follows:

	Years Ended June 30,
	2021			2020
Balance, beginning	$	598,000		$	581,000
Additions		198,000			139,000
Amortization expense		(133,000	)		(122,000	)
Balance, ending	$	663,000		$	598,000

Based on the carrying value as of June 30, 2021, future amortization is expected to be approximately as follows:

Fiscal years ending June 30:
2022	$	102,000
2023		41,000
2024		36,000
2025		34,000
2026		34,000
Thereafter		416,000
Total	$	663,000

XML 27 R12.htm IDEA: XBRL DOCUMENT

Financing Arrangements

12 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Financing Arrangements

Note 6. Financing Arrangements

The Company has a credit facility that provides for a revolving line of credit and a term loan. Effective December 16, 2020, the Company renewed its $2,500,000 revolving line of credit. There was no outstanding principal balance on the line of credit as of June 30, 2021 or June 30, 2020. Interest on borrowings under the line of credit, if any, accrues at the prime rate (3.25% as of June 30, 2021) less 1.00% and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or 57.00% of eligible accounts receivable and the line of credit expires on December 18, 2021, if not renewed. As of June 30, 2021, the maximum $2,500,000 was eligible for borrowing. The line of credit is secured by a security interest in substantially all the tangible and intangible assets of the Company.

The documents governing the line of credit contain certain financial and nonfinancial covenants that include a minimum tangible net worth covenant of not less than $10,125,000 and restrictions on the Company’s ability to incur certain additional indebtedness or pay dividends.

XML 28 R13.htm IDEA: XBRL DOCUMENT

Common Stock

12 Months Ended

Jun. 30, 2021

Equity [Abstract]

Common Stock

Note 7. Common Stock

Authorized shares: The Company’s Articles of Incorporation, as amended, have established 15,000,000 authorized shares of capital stock consisting of 13,000,000 shares of common stock, par value $0.01 per share, and 2,000,000 shares of undesignated stock.

On May 26, 2021 the Company’s Board of Directors (the “Board”) approved a stock repurchase authorization. Under the authorization, the Company may repurchase up to $3.0 million of shares of common stock through May 26, 2022. As of June 30, 2021, a total of 104,211 shares have been repurchased and retired under this authorization for a total cost of $1,124,000, or $10.79 per share. As of June 30, 2021, there were an additional $1,876,000 of shares of common stock available to be repurchased by the Company under the authorization. Repurchased shares have been retired and constitute authorized but unissued shares.

XML 29 R14.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

12 Months Ended

Jun. 30, 2021

Share-based Payment Arrangement [Abstract]

Share-Based Compensation

Note 8. Share-Based Payments

Share-based compensation expense for fiscal 2021 and 2020 was approximately $1,024,000 and $902,000, respectively, related to employee stock options and restricted stock awards. As of June 30, 2021, the Company had approximately $553,000 of unrecognized compensation expense related to non-vested equity awards, which is expected to be recognized over a weighted-average period of 0.9 years.

Employee options: The Company has historically granted stock options to employees as long-term incentive compensation. Options expire ten years from the grant date and vest over a period of three years. In November 2017, the Company’s shareholders approved the 2017 Omnibus Incentive Plan (the “2017 Plan”) which supersedes the 2014 Equity Incentive Plan (the “2014 Plan”). The 2017 Plan allows the Board to grant stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards, as well as cash incentive awards to all employees, non-employee directors, and advisors or consultants of the Company. The vesting schedule and term for each award are determined by the Board upon each grant. The maximum number of shares of common stock available for issuance under the 2017 Plan is 900,000. There were 258,500 options granted under the 2014 Plan and prior plans outstanding as of June 30, 2021. There were 209,549 options issued under the 2017 Plan outstanding and 476,224 shares available for grant under the 2017 Plan as of June 30, 2021.

The Company recognizes compensation expense related to share-based payment transactions in the financial statements based on the estimated fair value of the award issued. The fair value of each option is estimated using the Black-Scholes pricing model at the time of award grant. The Company estimates the expected life of options based on the expected holding period by the option holder. The risk-free interest rate is based upon observed U.S. Treasury interest rates for the expected term of the options. The Company makes assumptions with respect to expected stock price volatility based upon the historical volatility of its stock price. Forfeitures are estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from initial estimates. Forfeitures are estimated based on the percentage of awards expected to vest, taking into consideration the seniority level of the award recipient.

The following assumptions were used to estimate the fair value of options granted:

	Years Ended June 30,
	2021			2020
Risk-free interest rate		0.31-0.59	%		1.85	%
Expected term (years)		6			6
Expected volatility		283-335	%		190	%

The following table presents employee stock option activity for fiscal 2021 and 2020:

	Number of Shares			Weighted- Average Grant Date Fair Value		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (in Years)
Options outstanding as of June 30, 2019		683,000		$	3.35	$	3.84	6.96
Granted		149,300		$	5.19	$	5.29	—
Exercised		(194,670	)	$	2.47	$	3.08	—
Canceled or Forfeited		(46,850	)	$	5.16	$	5.34	—
Options outstanding as of June 30, 2020		590,780		$	3.96	$	4.34	6.87

Granted		61,017		$	14.13	$	14.14	—
Exercised		(71,150	)	$	4.78	$	5.09	—
Canceled or Forfeited		(112,598	)	$	6.24	$	6.50	—
Options outstanding as of June 30, 2021		468,049		$	4.61	$	4.98	5.82
Options exercisable as of June 30, 2021		442,437		$	4.16	$	4.54	5.64

The intrinsic value of a stock option is the amount by which the fair value of the underlying stock exceeds its exercise price. As of June 30, 2021, the weighted average remaining contractual term for all outstanding stock options was 5.8 years and their aggregate intrinsic value was $3,094,000. Outstanding as of June 30, 2021 were 468,049 stock options issued to employees, of which 442,437 were vested and exercisable and had an aggregate intrinsic value of $3,074,000.

Restricted stock: The 2017 Plan permits the Personnel and Compensation Committee of the Board to grant other stock-based awards, including shares of restricted stock. The Company makes restricted stock grants to key employees and non-employee directors that vest over six months to three years following the applicable grant date.

The Company issued restricted stock awards to employees totaling 30,756 and 35,000 during fiscal 2021 and 2020, respectively, with a vesting term of one to three years and a fair value of $14.68 and $5.84 per share, respectively. During fiscal 2021 and 2020, the Company issued restricted stock awards to directors totaling 18,000 each year, with a vesting term of six months and a fair value of $9.94 and $9.74 per share, respectively. Restricted stock transactions during the years ended June 30, 2021 and 2020 are summarized as follows:

	Shares of Restricted Stock			Weighted-Average Grant Date Fair Value per Share
Outstanding as of June 30, 2019		29,998		$	5.46
Granted		53,000		$	7.17
Vested		(45,833	)	$	6.83
Forfeited		(14,666	)	$	6.23
Outstanding as of June 30, 2020		22,499		$	6.19
Granted		48,756		$	12.93
Vested		(40,752	)	$	9.47
Outstanding as of June 30, 2021		30,503		$	12.57

XML 30 R15.htm IDEA: XBRL DOCUMENT

Income Taxes

12 Months Ended

Jun. 30, 2021

Income Tax Disclosure [Abstract]

Income Taxes

Note 9. Income Taxes

Components of the provision for income taxes for fiscal 2021 and 2020 were as follows:

	Years Ended June 30,
	2021			2020
Current:
Current Federal	$	861,000		$	922,000
Current State		238,000			282,000
Total Current		1,099,000			1,204,000
Deferred:
Deferred Federal		(204,000	)		(70,000	)
Deferred State		(90,000	)		(56,000	)
Total Deferred		(294,000	)		(126,000	)

Total Income Tax Expense	$	805,000		$	1,078,000

The total income tax expense differed from the expected tax expense, computed by applying the federal statutory rate to the Company’s pretax income, as follows:

	Years Ended June 30,
	2021			2020
Tax expense at statutory federal rate	$	665,000		$	1,100,000
State income tax expense, net of federal tax effect		110,000			151,000
Change in valuation allowance on deferred tax assets		34,000			91,000
Other permanent items		(4,000	)		(264,000	)
Income tax expense	$	805,000		$	1,078,000

The effective tax rates for fiscal 2021 and 2020 were 25.4% and 20.6%, respectively.

The significant components of deferred income taxes were as follows:

	June 30,
	2021			2020
Deferred tax assets (liabilities):
Revenue recognition and accounts receivable reserves	$	655,000		$	468,000
Accrued liabilities		297,000			253,000
Property and equipment		(218,000	)		(202,000	)
Finite-life intangible assets		(15,000	)		(6,000	)
Stock options		414,000			458,000
Tax credits		125,000			92,000
Accounting method change		(140,000	)		(282,000	)
Valuation allowance on deferred taxes		(125,000	)		(91,000	)
Other		56,000			65,000
Net deferred tax assets	$	1,049,000		$	755,000

The Company has state tax credits of $125,000, net of federal taxes, which if unused, will begin to expire in calendar years 2026 and 2034. The Company has taken a full valuation allowance against these credits which relate to research and development tax credits in Minnesota, a state in which the Company has a low state apportionment factor.

The Company applies the accounting standard for uncertain tax positions pursuant to which a more-likely-than-not threshold is utilized to determine the recognition and derecognition of uncertain tax positions. Once the more-likely-than-not threshold is met, the amount of benefit to be recognized is the largest amount of tax benefit that is greater than 50 percent likely of being ultimately realized upon settlement. It further requires that a change in judgment related to the expected ultimate resolution of uncertain tax positions be recognized in earnings in the period of such a change. The Company does not have any uncertain tax positions as of June 30, 2021 and June 30, 2020.

The Company is subject to U.S. federal income tax as well as income tax of multiple state jurisdictions. With limited exceptions, tax years prior to the Company’s fiscal year ended June 30, 2018 are no longer open to federal, state and local examination by taxing authorities.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 31 R16.htm IDEA: XBRL DOCUMENT

Leases

12 Months Ended

Jun. 30, 2021

Leases [Abstract]

Leases

Note 10. Leases

The Company has six leases for office and warehouse space that require monthly payments. These leases have escalating payments ranging from approximately $200 to $4,400 per month which expire through January 2026 and are recognized on a straight-line basis over the life of the lease. The Company has a lease for office equipment that requires payments of approximately $1,600 per month through August 2022. All leases are classified as operating leases which do not include renewal options. The Company currently does not have any short-term or variable lease costs. The Company applied the practical expedient to calculate the present value of the fixed payments without having to perform an allocation to lease and non-lease components.

The Company has recognized right of use assets associated with its operating leases of approximately $88,000 and $81,000 as of June 30, 2021 and June 30, 2020, respectively, which is included in other assets on the Company’s balance sheet. Operating lease liabilities were $87,000 and $81,000 as of June 30, 2021 and June 30, 2020, respectively, which are included in current maturities of long-term liabilities and other long-term liabilities on the Company’s balance sheet.

As of June 30, 2021, the Company has a weighted-average lease term of 2.8 years for its operating leases, which have a weighted-average discount rate of 4.0%. Operating lease payments of $74,000 are included in operating cash flows in fiscal 2021.

Maturities of lease liabilities, which are included in current maturities of long-term liabilities and other long-term liabilities on the Company’s balance sheet, are as follows:

Fiscal years ending June 30:
2022	$	29,000
2023		18,000
2024		17,000
2025		17,000
2026		8,000
Total lease payments		89,000
Less: Interest		(2,000	)
Present value of lease liabilities	$	87,000

XML 32 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

12 Months Ended

Jun. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 11. Commitments and Contingencies

Litigation: The Company may occasionally be party to actions, proceedings, claims or disputes arising in the ordinary course of business. The Company insures certain business risks where possible to mitigate the financial impact of individual claims and establishes reserves for an estimate of any probable cost of settlement or other disposition.

401(k) Profit Sharing Plan: The Company has an employee benefit plan under Section 401(k) of the Internal Revenue Code covering all employees who are 21 years of age or older and have at least 1,000 hours of service with the Company. The Company matches each employee’s salary reduction contribution, not to exceed four percent of annual compensation. Total employer contributions to this plan for fiscal 2021 and 2020 were approximately $399,000 and $329,000, respectively.

Employment Agreements: The Company has entered into formal employment agreements with its President and Chief Executive Officer and its Chief Financial Officer, as amended from time to time. These agreements provide these officers with, among other things, twelve to eighteen months of base salary upon a termination without “Cause” or in the event the employee resigns for “Good Reason” or within twelve months of a “Change in Control,” as such terms are defined in the respective employment agreements.

XML 33 R18.htm IDEA: XBRL DOCUMENT

Nature of Business and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Use of estimates

COVID-19 Pandemic and CARES Act Funding

COVID-19 Pandemic and CARES Act Funding

Revenue recognition

Shipping and handling expense

Shipping and handling expense: Shipping and handling charges incurred by the Company are included in cost of revenues and were $530,000 and $515,000 for fiscal 2021 and 2020, respectively.

Cash and cash equivalents

Accounts receivable

Contract assets

Inventories

Property and equipment

Finite-life intangible assets

Long-lived assets

Warranty liability

Changes in the Company’s warranty liability were approximately as follows:

	Years Ended June 30,
	2021			2020
Beginning warranty reserve	$	740,000		$	810,000
Accrual for products sold		354,000			79,000
Expenditures and costs incurred for warranty claims		(154,000	)		(149,000	)
Ending warranty reserve	$	940,000		$	740,000

Income taxes

Research and development

Advertising costs

Share-based payments

Fair value of financial instruments

Basic and diluted earnings per share

XML 34 R19.htm IDEA: XBRL DOCUMENT

Nature of Business and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Schedule of changes in warranty liability

Changes in the Company’s warranty liability were approximately as follows:

	Years Ended June 30,
	2021			2020
Beginning warranty reserve	$	740,000		$	810,000
Accrual for products sold		354,000			79,000
Expenditures and costs incurred for warranty claims		(154,000	)		(149,000	)
Ending warranty reserve	$	940,000		$	740,000

XML 35 R20.htm IDEA: XBRL DOCUMENT

Revenues (Tables)

12 Months Ended

Jun. 30, 2021

Revenue from Contract with Customer [Abstract]

Schedule of disaggregated revenue

In the following table, revenue is disaggregated by market:

	Fiscal Year Ended June 30,
	2021		2020
Home Care	$	32,986,000	$	29,323,000
Institutional		1,549,000		2,000,000
Home Care Distributor		563,000		430,000
International		658,000		718,000
Total	$	35,756,000	$	32,471,000

In the following table, home care revenue is disaggregated by payer type:

	Fiscal Year Ended June 30,
	2021		2020
Commercial	$	12,530,000	$	11,728,000
Medicare		19,044,000		14,863,000
Medicaid		846,000		1,696,000
Other		566,000		1,036,000
Total	$	32,986,000	$	29,323,000

Schedule of contract assets

The following table provides information about accounts receivable and contracts assets from contracts with customers:

	June 30, 2021		June 30, 2020
Receivables, included in “Accounts receivable, net of allowance for doubtful accounts”	$	17,032,000	$	12,941,000
Contract assets	$	393,000	$	903,000

Significant changes in contract assets during the period are as follows:

	Fiscal Year Ended			Fiscal Year Ended
	June 30, 2021			June 30, 2020
	Increase (decrease)			Increase (decrease)
Contract assets, beginning	$	903,000		$	996,000
Reclassification of contract assets to accounts receivable		(1,551,000	)		(1,858,000	)
Contract assets recognized		1,060,000			1,734,000
Increase (decrease) as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period		(19,000	)		31,000
Contract assets, ending	$	393,000		$	903,000

XML 36 R21.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

12 Months Ended

Jun. 30, 2021

Inventory Disclosure [Abstract]

Schedule of components of inventories

The components of inventories as of June 30, 2021 and 2020 were approximately as follows:

	June 30,
	2021			2020
Parts inventory	$	1,779,000		$	2,271,000
Work in process		23,000			127,000
Finished goods		445,000			827,000
Estimated inventory to be returned		167,000			150,000
Less: Reserve for obsolescence		(300,000	)		(290,000	)
Total	$	2,114,000		$	3,085,000

XML 37 R22.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

12 Months Ended

Jun. 30, 2021

Property, Plant and Equipment [Abstract]

Schedule of property and equipment, including assets under capital leases

Property and equipment were approximately as follows:

	Estimated Useful		June 30,
	Lives (Years)		2021			2020
Building and building improvements		15-39	$	3,446,000		$	3,437,000
Land		N/A		200,000			200,000
Land improvements		15		166,000			166,000
Equipment		3-7		3,467,000			3,311,000
Demonstration and rental equipment		3		1,060,000			1,075,000
Construction in progress		N/A		26,000			16,000
				8,365,000			8,205,000
Less: Accumulated depreciation				(4,760,000	)		(4,417,000	)
Net property and equipment			$	3,605,000		$	3,788,000

XML 38 R23.htm IDEA: XBRL DOCUMENT

Finite-life Intangible Assets (Tables)

12 Months Ended

Jun. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of activity and balances of finite-life intangible assets

The activity and net balances of finite-life intangible assets were approximately as follows:

	Years Ended June 30,
	2021			2020
Balance, beginning	$	598,000		$	581,000
Additions		198,000			139,000
Amortization expense		(133,000	)		(122,000	)
Balance, ending	$	663,000		$	598,000

Schedule of future amortization of finite-life intangible assets

Based on the carrying value as of June 30, 2021, future amortization is expected to be approximately as follows:

Fiscal years ending June 30:
2022	$	102,000
2023		41,000
2024		36,000
2025		34,000
2026		34,000
Thereafter		416,000
Total	$	663,000

XML 39 R24.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

12 Months Ended

Jun. 30, 2021

Share-based Payment Arrangement [Abstract]

Schedule of assumptions used to estimate fair value of options granted

The following assumptions were used to estimate the fair value of options granted:

	Years Ended June 30,
	2021			2020
Risk-free interest rate		0.31-0.59	%		1.85	%
Expected term (years)		6			6
Expected volatility		283-335	%		190	%

Schedule of stock option transactions

The following table presents employee stock option activity for fiscal 2021 and 2020:

	Number of Shares			Weighted- Average Grant Date Fair Value		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (in Years)
Options outstanding as of June 30, 2019		683,000		$	3.35	$	3.84	6.96
Granted		149,300		$	5.19	$	5.29	—
Exercised		(194,670	)	$	2.47	$	3.08	—
Canceled or Forfeited		(46,850	)	$	5.16	$	5.34	—
Options outstanding as of June 30, 2020		590,780		$	3.96	$	4.34	6.87

Granted		61,017		$	14.13	$	14.14	—
Exercised		(71,150	)	$	4.78	$	5.09	—
Canceled or Forfeited		(112,598	)	$	6.24	$	6.50	—
Options outstanding as of June 30, 2021		468,049		$	4.61	$	4.98	5.82
Options exercisable as of June 30, 2021		442,437		$	4.16	$	4.54	5.64

Schedule of restricted stock transactions

Restricted stock transactions during the years ended June 30, 2021 and 2020 are summarized as follows:

	Shares of Restricted Stock			Weighted-Average Grant Date Fair Value per Share
Outstanding as of June 30, 2019		29,998		$	5.46
Granted		53,000		$	7.17
Vested		(45,833	)	$	6.83
Forfeited		(14,666	)	$	6.23
Outstanding as of June 30, 2020		22,499		$	6.19
Granted		48,756		$	12.93
Vested		(40,752	)	$	9.47
Outstanding as of June 30, 2021		30,503		$	12.57

XML 40 R25.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

12 Months Ended

Jun. 30, 2021

Income Tax Disclosure [Abstract]

Schedule of components of the provision for income taxes

Components of the provision for income taxes for fiscal 2021 and 2020 were as follows:

	Years Ended June 30,
	2021			2020
Current:
Current Federal	$	861,000		$	922,000
Current State		238,000			282,000
Total Current		1,099,000			1,204,000
Deferred:
Deferred Federal		(204,000	)		(70,000	)
Deferred State		(90,000	)		(56,000	)
Total Deferred		(294,000	)		(126,000	)

Total Income Tax Expense	$	805,000		$	1,078,000

Schedule of effective income tax reconciliation

The total income tax expense differed from the expected tax expense, computed by applying the federal statutory rate to the Company’s pretax income, as follows:

	Years Ended June 30,
	2021			2020
Tax expense at statutory federal rate	$	665,000		$	1,100,000
State income tax expense, net of federal tax effect		110,000			151,000
Change in valuation allowance on deferred tax assets		34,000			91,000
Other permanent items		(4,000	)		(264,000	)
Income tax expense	$	805,000		$	1,078,000

Schedule of significant components of deferred income taxes

The significant components of deferred income taxes were as follows:

	June 30,
	2021			2020
Deferred tax assets (liabilities):
Revenue recognition and accounts receivable reserves	$	655,000		$	468,000
Accrued liabilities		297,000			253,000
Property and equipment		(218,000	)		(202,000	)
Finite-life intangible assets		(15,000	)		(6,000	)
Stock options		414,000			458,000
Tax credits		125,000			92,000
Accounting method change		(140,000	)		(282,000	)
Valuation allowance on deferred taxes		(125,000	)		(91,000	)
Other		56,000			65,000
Net deferred tax assets	$	1,049,000		$	755,000

XML 41 R26.htm IDEA: XBRL DOCUMENT

Leases (Tables)

12 Months Ended

Jun. 30, 2021

Leases [Abstract]

Schedule of maturities of lease liabilities

Maturities of lease liabilities, which are included in current maturities of long-term liabilities and other long-term liabilities on the Company’s balance sheet, are as follows:

Fiscal years ending June 30:
2022	$	29,000
2023		18,000
2024		17,000
2025		17,000
2026		8,000
Total lease payments		89,000
Less: Interest		(2,000	)
Present value of lease liabilities	$	87,000

XML 42 R27.htm IDEA: XBRL DOCUMENT

Nature of Business and Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Accounting Policies [Abstract]
Beginning warranty reserve	$ 740,000	$ 810,000
Accrual for products sold	354,000	79,000
Expenditures and costs incurred for warranty claims	(154,000)	(149,000)
Ending warranty reserve	$ 940,000	$ 740,000

XML 43 R28.htm IDEA: XBRL DOCUMENT

Nature of Business and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Sales	$ 35,756,000	$ 32,471,000
Common stock equivalents excluded from calculation of diluted earnings per share	48,617	0
Cost of revenue	$ 8,451,000	$ 7,271,000
Advertising, marketing and trade show costs	1,062,000	781,000
Accounts receivable, allowance for doubtful accounts	45,000	45,000
International [Member]
Sales	658,000	718,000
Shipping and Handling [Member]
Cost of revenue	$ 530,000	$ 515,000

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

XML 44 R29.htm IDEA: XBRL DOCUMENT

Revenues (Details) - USD ($)	12 Months Ended
Revenues (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Revenue	$ 35,756,000	$ 32,471,000
Home Care [Member]
Revenue	32,986,000	29,323,000
Home Care [Member] \| Commercial [Member]
Revenue	12,530,000	11,728,000
Home Care [Member] \| Medicare [Member]
Revenue	19,044,000	14,863,000
Home Care [Member] \| Medicaid [Member]
Revenue	846,000	1,696,000
Home Care [Member] \| Other [Member]
Revenue	566,000	1,036,000
Institutional [Member]
Revenue	1,549,000	2,000,000
Home Care Distributor [Member]
Revenue	563,000	430,000
International [Member]
Revenue	$ 658,000	$ 718,000

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 45 R30.htm IDEA: XBRL DOCUMENT

Revenues (Details 1) - USD ($)	12 Months Ended
Revenues (Details 1) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Receivables, included in "Accounts receivable, net of allowance for doubtful accounts"	$ 17,032,000	$ 12,941,000
Contract assets	393,000	903,000
Contract assets, beginning	903,000	996,000
Reclassification contract assets to accounts receivable	(1,551,000)	(1,858,000)
Contract assets recognized	1,060,000	1,734,000
Increase (decrease) as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period	(19,000)	31,000
Contract assets, ending	$ 393,000	$ 903,000

XML 46 R31.htm IDEA: XBRL DOCUMENT

Revenues (Details Narrative) - USD ($)	12 Months Ended
Revenues (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Operating lease revenue	$ 1,000	$ 6,000

XML 47 R32.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Inventory Disclosure [Abstract]
Parts inventory	$ 1,779,000	$ 2,271,000
Work in process	23,000	127,000
Finished goods	445,000	827,000
Estimated Inventory to be returned	167,000	150,000
Less: Reserve for obsolescence	(300,000)	(290,000)
Total	$ 2,114,000	$ 3,085,000

XML 48 R33.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($)	12 Months Ended
Property and Equipment (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Property and equipment, gross	$ 8,365,000	$ 8,205,000
Less: Accumulated depreciation	(4,760,000)	(4,417,000)
Net property and equipment	3,605,000	3,788,000
Building and Building Improvements [Member]
Property and equipment, gross	$ 3,446,000	3,437,000
Building and Building Improvements [Member] \| Minimum [Member]
Estimated useful life	15 years
Building and Building Improvements [Member] \| Maximum [Member]
Estimated useful life	39 years
Land Improvements [Member]
Property and equipment, gross	$ 166,000	166,000
Estimated useful life	15 years
Equipment [Member]
Property and equipment, gross	$ 3,467,000	3,311,000
Equipment [Member] \| Minimum [Member]
Estimated useful life	3 years
Equipment [Member] \| Maximum [Member]
Estimated useful life	7 years
Demonstration and Rental Equipment [Member]
Property and equipment, gross	$ 1,060,000	1,075,000
Estimated useful life	3 years
Land [Member]
Property and equipment, gross	$ 200,000	200,000
Construction in Progress [Member]
Property and equipment, gross	$ 26,000	$ 16,000

XML 49 R34.htm IDEA: XBRL DOCUMENT

Finite-life Intangible Assets (Details) - USD ($)	12 Months Ended
Finite-life Intangible Assets (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Balance, beginning	$ 598,000	$ 581,000
Additions	198,000	139,000
Amortization expense	(133,000)	(122,000)
Balance, ending	$ 663,000	$ 598,000

XML 50 R35.htm IDEA: XBRL DOCUMENT

Finite-life Intangible Assets (Details 1) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Fiscal years ending June 30:
2022	$ 102,000
2023	41,000
2024	36,000
2025	34,000
2026	34,000
Thereafter	416,000
Total	$ 663,000	$ 598,000	$ 581,000

XML 51 R36.htm IDEA: XBRL DOCUMENT

Finite-life Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Accumulated amortization	$ 1,248,000	$ 1,119,000
Patents [Member]
Estimated useful life	15 years
Trademarks [Member]
Estimated useful life	12 years

XML 52 R37.htm IDEA: XBRL DOCUMENT

Financing Arrangements (Details Narrative) - USD ($)	12 Months Ended
Financing Arrangements (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Minimum tangible net worth to be maintained	$ 10,125,000
Credit Facility [Member]
Maximum borrowing capacity	2,500,000
Line of credit balance	$ 0	$ 0
Credit facility effective date	Dec. 16, 2020
Credit facility expiration date	Dec. 16, 2021
Basis spread on rate	1.00%
Borrowing capacity of eligible accounts receivable	$ 2,500,000
Borrowing capacity of eligible accounts receivable (percent)	57.00%
Available borrowing capacity	$ 2,500,000
Credit Facility [Member] \| Prime Rate [Member]
Interest rate	3.25%

XML 53 R38.htm IDEA: XBRL DOCUMENT

Common Stock (Details Narrative) - USD ($)	12 Months Ended
Common Stock (Details Narrative) - USD ($)	Jun. 30, 2021	May 26, 2021	Jun. 30, 2020
Common stock, shares authorized	13,000,000		13,000,000
Common stock, par value	$ 0.01		$ 0.01
Vaue of repurchased	$ (1,124,000)
Number of share repurchased	(104,211)
Share price	$ 10.79
Board of Directors [Member]
Common stock, shares authorized		3,000,000
Undesignated Stock [Member]
Common stock, shares authorized	2,000,000
Common Stock [Member]
Common stock, shares authorized	13,000,000
Common stock, par value	$ 0.01
Number of share repurchased	(1,876,000)
Capital Stock [Member]
Common stock, shares authorized	15,000,000

XML 54 R39.htm IDEA: XBRL DOCUMENT

Share-Based Payments (Details) - Stock Options [Member]	12 Months Ended
Share-Based Payments (Details) - Stock Options [Member]	Jun. 30, 2021	Jun. 30, 2020
Risk free interest rate - minimum	0.31%
Risk free interest rate - maximum	0.59%
Risk free interest rate		1.85%
Expected term (year)	6 years	6 years
Expected volatility		190.00%
Expected volatility - minimum	283.00%
Expected volatility - maximum	335.00%

XML 55 R40.htm IDEA: XBRL DOCUMENT

Share-Based Payments (Details 1) - $ / shares	12 Months Ended
Share-Based Payments (Details 1) - $ / shares	Jun. 30, 2021	Jun. 30, 2020
Number of Shares
Options outstanding, ending	442,437
Options exercisable, ending	468,049
Stock Options [Member]
Number of Shares
Options outstanding, beginning	590,780	683,000
Granted	61,017	149,300
Exercised	(71,150)	(194,670)
Cancelled or Forfeited	(112,598)	(46,850)
Options outstanding, ending	468,049	590,780
Options exercisable, ending	442,437
Weighted Average Grant Date Fair Value
Options outstanding, beginning	$ 3.96	$ 3.35
Granted	14.13	5.19
Exercised	4.78	2.47
Cancelled or Forfeited	6.24	5.16
Options outstanding, ending	4.61	3.96
Options exercisable, ending	4.16
Weighted Average Exercise Price
Options outstanding, beginning	4.34	3.84
Granted	14.14	5.29
Exercised	5.09	3.08
Cancelled or Forfeited	6.50	5.34
Options outstanding, ending	4.98	$ 4.34
Options exercisable, ending	$ 4.54
Weighted-Average Remaining Contractual Life
Options outstanding at beginning	6 years 10 months 14 days	6 years 11 months 15 days
Option outstanding at ending	5 years 9 months 25 days	6 years 10 months 14 days
Options exercisable	5 years 7 months 21 days

XML 56 R41.htm IDEA: XBRL DOCUMENT

Share-Based Payments (Details 2) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Number of Shares
Outstanding, beginning	22,499	29,998
Granted	48,756	53,000
Vested	(40,752)	(45,833)
Forfeited		(14,666)
Outstanding, ending	30,503	22,499
Weighted Average Grant Date Fair Value
Outstanding, beginning	$ 6.19	$ 5.46
Granted	12.93	7.17
Vested	9.47	6.83
Forfeited		6.23
Outstanding, ending	$ 12.57	$ 6.19

XML 57 R42.htm IDEA: XBRL DOCUMENT

Share-Based Payments (Details Narrative) - USD ($)	12 Months Ended
Share-Based Payments (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Share-based compensation expense	$ 1,024,000	$ 902,000
Unrecognized compensation expense	$ 553,000
Unrecognized compensation expense, period for recognition	10 months 25 days
Options outstanding, intrinsic value	$ 3,094,000
Options exercisable, intrinsic value	$ 3,074,000
Outstanding exercisable	468,049
Options outstanding	442,437
Restricted Stock [Member]
Restricted stock awards issued	48,756	53,000
Fair value on grant date	$ 12.93	$ 7.17
Restricted Stock [Member] \| Director [Member]
Restricted stock awards issued	18,000	10,000
Vesting term of awards	6 months	6 months
Fair value on grant date	$ 9.94	$ 9.74
2017 Plan [Member]
Shares available for issuance	900,000
Available for grant, shares	476,224
Options outstanding (shares)	209,549
2014 Plan [Member]
Available for grant, shares	258,500
Employees [Member] \| Restricted Stock [Member]
Restricted stock awards issued	30,756	35,000
Fair value on grant date	$ 14.68	$ 5.84
Employees [Member] \| Restricted Stock [Member] \| Minimum [Member]
Vesting term of awards	1 year
Options expire	5 years
Employees [Member] \| Restricted Stock [Member] \| Maximum [Member]
Vesting term of awards	3 years
Options expire	10 years

XML 58 R43.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Current:
Current Federal	$ 861,000	$ 922,000
Current State	238,000	282,000
Total Current	1,099,000	1,204,000
Deferred:
Deferred Federal	(204,000)	(70,000)
Deferred State	(90,000)	(56,000)
Total Deferred	(294,000)	(126,000)
Total Income Tax Expense	$ 805,000	$ 1,078,000

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 59 R44.htm IDEA: XBRL DOCUMENT

Income Taxes (Details 1) - USD ($)	12 Months Ended
Income Taxes (Details 1) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Tax expense at statutory federal rate	$ 665,000	$ 1,100,000
State income tax expense, net of federal tax effect	110,000	151,000
Change in valuation allowance on deferred tax assets	34,000	91,000
Other permanent items	(4,000)	(264,000)
Income tax expense	$ 805,000	$ 1,078,000

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 60 R45.htm IDEA: XBRL DOCUMENT

Income Taxes (Details 2) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Deferred tax assets (liabilities):
Revenue recognition and accounts receivable reserves	$ 655,000	$ 468,000
Accrued liabilities	297,000	253,000
Property and equipment	(218,000)	(202,000)
Finite-life intangible assets	(15,000)	(6,000)
Stock options	414,000	458,000
Tax credits	125,000	92,000
Accounting method change	(140,000)	(282,000)
Valuation allowance on deferred taxes	(125,000)	(91,000)
Other	56,000	65,000
Net deferred tax assets	$ 1,049,000	$ 755,000

XML 61 R46.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Income tax expense	$ 805,000	$ 1,078,000
Effective tax rate	25.40%	20.60%
State Jurisdiction [Member]
Tax credit carryforwards	$ 125,000

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 62 R47.htm IDEA: XBRL DOCUMENT

Leases (Details)	Jun. 30, 2021 USD ($)
Fiscal years ending June 30:
2022	$ 29,000
2023	18,000
2024	17,000
2025	17,000
2026	8,000
Total lease payments	89,000
Less: Interest	(2,000)
Present value of lease liabilities	$ 87,000

XML 63 R48.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative) - USD ($)	12 Months Ended
Leases (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Operating lease payment	$ 74,000
Operating lease right of use asset	88,000	$ 81,000
Operating lease liability	$ 87,000
Weighted-average lease term	2 years 9 months 18 days
Weighted-average discount rate	4.00%
Other Liabilities [Member]
Operating lease liability	$ 87,000	$ 81,000
Office and Warehouse Space [Member]
Lease expiration date	Jan. 31, 2026
Office and Warehouse Space [Member] \| Minimum [Member]
Operating lease payment	$ 200
Office and Warehouse Space [Member] \| Maximum [Member]
Operating lease payment	4,400
Office Equipment [Member]
Operating lease payment	$ 1,600
Lease expiration date	Aug. 31, 2022

XML 64 R49.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative)	12 Months Ended
Commitments and Contingencies (Details Narrative)	Jun. 30, 2021 USD ($) Number	Jun. 30, 2020 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Employee benefit plan, minimum age requirement	21 years
Employee benefit plan, requisite service hours \| Number	1,000
Employee benefit plan, employer contribution \| $	$ 399,000	$ 329,000

EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 66 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 / / v2.2.0.24 / / DefRef Styles / ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } / Report Styles / ..pl a, .pl a:visited { color: black; text-decoration: none; } / table / ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } / Top labels / ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; / word-wrap: break-word; / } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } / Header rows... / ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } / Calendars... / ..report .rc { background-color: #f0f0f0; } / Even rows... / ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } / Odd rows... / ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } / styles for footnote marker / ..report .fn { white-space: nowrap; } / styles for numeric types / ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } / styles for text types / ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 96 339 1 false 39 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://electromed.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://electromed.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://electromed.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://electromed.com/role/StatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Statements of Shareholders' Equity Sheet http://electromed.com/role/StatementsOfShareholdersEquity Statements of Shareholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Statements of Cash Flows Sheet http://electromed.com/role/StatementsOfCashFlows Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Nature of Business and Summary of Significant Accounting Policies Sheet http://electromed.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPolicies Nature of Business and Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Revenues Sheet http://electromed.com/role/Revenues Revenues Notes 8 false false R9.htm 00000009 - Disclosure - Inventories Sheet http://electromed.com/role/Inventories Inventories Notes 9 false false R10.htm 00000010 - Disclosure - Property and Equipment Sheet http://electromed.com/role/PropertyAndEquipment Property and Equipment Notes 10 false false R11.htm 00000011 - Disclosure - Finite-life Intangible Assets Sheet http://electromed.com/role/Finite-lifeIntangibleAssets Finite-life Intangible Assets Notes 11 false false R12.htm 00000012 - Disclosure - Financing Arrangements Sheet http://electromed.com/role/FinancingArrangements Financing Arrangements Notes 12 false false R13.htm 00000013 - Disclosure - Common Stock Sheet http://electromed.com/role/CommonStock Common Stock Notes 13 false false R14.htm 00000014 - Disclosure - Stock-Based Compensation Sheet http://electromed.com/role/Stock-basedCompensation Stock-Based Compensation Notes 14 false false R15.htm 00000015 - Disclosure - Income Taxes Sheet http://electromed.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 00000016 - Disclosure - Leases Sheet http://electromed.com/role/Leases Leases Notes 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies Sheet http://electromed.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Policies) Sheet http://electromed.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies Nature of Business and Summary of Significant Accounting Policies (Policies) Policies http://electromed.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Tables) Sheet http://electromed.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables Nature of Business and Summary of Significant Accounting Policies (Tables) Tables http://electromed.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Revenues (Tables) Sheet http://electromed.com/role/RevenuesTables Revenues (Tables) Tables http://electromed.com/role/Revenues 20 false false R21.htm 00000021 - Disclosure - Inventories (Tables) Sheet http://electromed.com/role/InventoriesTables Inventories (Tables) Tables http://electromed.com/role/Inventories 21 false false R22.htm 00000022 - Disclosure - Property and Equipment (Tables) Sheet http://electromed.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://electromed.com/role/PropertyAndEquipment 22 false false R23.htm 00000023 - Disclosure - Finite-life Intangible Assets (Tables) Sheet http://electromed.com/role/Finite-lifeIntangibleAssetsTables Finite-life Intangible Assets (Tables) Tables http://electromed.com/role/Finite-lifeIntangibleAssets 23 false false R24.htm 00000024 - Disclosure - Stock-Based Compensation (Tables) Sheet http://electromed.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://electromed.com/role/Stock-basedCompensation 24 false false R25.htm 00000025 - Disclosure - Income Taxes (Tables) Sheet http://electromed.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://electromed.com/role/IncomeTaxes 25 false false R26.htm 00000026 - Disclosure - Leases (Tables) Sheet http://electromed.com/role/LeasesTables Leases (Tables) Tables http://electromed.com/role/Leases 26 false false R27.htm 00000027 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Details) Sheet http://electromed.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetails Nature of Business and Summary of Significant Accounting Policies (Details) Details http://electromed.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables 27 false false R28.htm 00000028 - Disclosure - Nature of Business and Summary of Significant Accounting Policies (Details Narrative) Sheet http://electromed.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Nature of Business and Summary of Significant Accounting Policies (Details Narrative) Details http://electromed.com/role/NatureOfBusinessAndSummaryOfSignificantAccountingPoliciesTables 28 false false R29.htm 00000029 - Disclosure - Revenues (Details) Sheet http://electromed.com/role/RevenuesDetails Revenues (Details) Details http://electromed.com/role/RevenuesTables 29 false false R30.htm 00000030 - Disclosure - Revenues (Details 1) Sheet http://electromed.com/role/RevenuesDetails1 Revenues (Details 1) Details http://electromed.com/role/RevenuesTables 30 false false R31.htm 00000031 - Disclosure - Revenues (Details Narrative) Sheet http://electromed.com/role/RevenuesDetailsNarrative Revenues (Details Narrative) Details http://electromed.com/role/RevenuesTables 31 false false R32.htm 00000032 - Disclosure - Inventories (Details) Sheet http://electromed.com/role/InventoriesDetails Inventories (Details) Details http://electromed.com/role/InventoriesTables 32 false false R33.htm 00000033 - Disclosure - Property and Equipment (Details) Sheet http://electromed.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://electromed.com/role/PropertyAndEquipmentTables 33 false false R34.htm 00000034 - Disclosure - Finite-life Intangible Assets (Details) Sheet http://electromed.com/role/Finite-lifeIntangibleAssetsDetails Finite-life Intangible Assets (Details) Details http://electromed.com/role/Finite-lifeIntangibleAssetsTables 34 false false R35.htm 00000035 - Disclosure - Finite-life Intangible Assets (Details 1) Sheet http://electromed.com/role/Finite-lifeIntangibleAssetsDetails1 Finite-life Intangible Assets (Details 1) Details http://electromed.com/role/Finite-lifeIntangibleAssetsTables 35 false false R36.htm 00000036 - Disclosure - Finite-life Intangible Assets (Details Narrative) Sheet http://electromed.com/role/Finite-lifeIntangibleAssetsDetailsNarrative Finite-life Intangible Assets (Details Narrative) Details http://electromed.com/role/Finite-lifeIntangibleAssetsTables 36 false false R37.htm 00000037 - Disclosure - Financing Arrangements (Details Narrative) Sheet http://electromed.com/role/FinancingArrangementsDetailsNarrative Financing Arrangements (Details Narrative) Details http://electromed.com/role/FinancingArrangements 37 false false R38.htm 00000038 - Disclosure - Common Stock (Details Narrative) Sheet http://electromed.com/role/CommonStockDetailsNarrative Common Stock (Details Narrative) Details http://electromed.com/role/CommonStock 38 false false R39.htm 00000039 - Disclosure - Share-Based Payments (Details) Sheet http://electromed.com/role/Share-basedPaymentsDetails Share-Based Payments (Details) Details 39 false false R40.htm 00000040 - Disclosure - Share-Based Payments (Details 1) Sheet http://electromed.com/role/Share-basedPaymentsDetails1 Share-Based Payments (Details 1) Details 40 false false R41.htm 00000041 - Disclosure - Share-Based Payments (Details 2) Sheet http://electromed.com/role/Share-basedPaymentsDetails2 Share-Based Payments (Details 2) Details 41 false false R42.htm 00000042 - Disclosure - Share-Based Payments (Details Narrative) Sheet http://electromed.com/role/Share-basedPaymentsDetailsNarrative Share-Based Payments (Details Narrative) Details 42 false false R43.htm 00000043 - Disclosure - Income Taxes (Details) Sheet http://electromed.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://electromed.com/role/IncomeTaxesTables 43 false false R44.htm 00000044 - Disclosure - Income Taxes (Details 1) Sheet http://electromed.com/role/IncomeTaxesDetails1 Income Taxes (Details 1) Details http://electromed.com/role/IncomeTaxesTables 44 false false R45.htm 00000045 - Disclosure - Income Taxes (Details 2) Sheet http://electromed.com/role/IncomeTaxesDetails2 Income Taxes (Details 2) Details http://electromed.com/role/IncomeTaxesTables 45 false false R46.htm 00000046 - Disclosure - Income Taxes (Details Narrative) Sheet http://electromed.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://electromed.com/role/IncomeTaxesTables 46 false false R47.htm 00000047 - Disclosure - Leases (Details) Sheet http://electromed.com/role/LeasesDetails Leases (Details) Details http://electromed.com/role/LeasesTables 47 false false R48.htm 00000048 - Disclosure - Leases (Details Narrative) Sheet http://electromed.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://electromed.com/role/LeasesTables 48 false false R49.htm 00000049 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://electromed.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://electromed.com/role/CommitmentsAndContingencies 49 false false All Reports Book All Reports elmd-20210630.xml elmd-20210630.xsd elmd-20210630_cal.xml elmd-20210630_def.xml elmd-20210630_lab.xml elmd-20210630_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true ZIP 70 0000897101-21-000726-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000897101-21-000726-xbrl.zip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end

Minnesota	41-1732920
(State or other jurisdiction of	(IRS Employer
incorporation or organization)	Identification No.)

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		ELMD		NYSE American

PART I		1
Item 1.	Business	1
Item 1A.	Risk Factors	13
Item 1B.	Unresolved Staff Comments	13
Item 2.	Properties	13
Item 3.	Legal Proceedings	13
Item 4.	Mine Safety Disclosures	13

PART II		13
Item 5.	Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	13
Item 6.	Selected Financial Data	14
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	22
Item 8.	Financial Statements and Supplementary Data	F-1
Item 9.	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	23
Item 9A.	Controls and Procedures	23
Item 9B.	Other Information	23

PART III		24
Item 10.	Directors, Executive Officers and Corporate Governance	24
Item 11.	Executive Compensation	24
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	25
Item 13.	Certain Relationships and Related Transactions, and Director Independence	25
Item 14.	Principal Accountant Fees and Services	25
Item 15.	Exhibits and Financial Statement Schedules	25
Item 16.	Form 10-K Summary	27

Exhibit
Number	Description	Method of Filing
3.1	Composite Articles of Incorporation, as amended through November 8, 2010 (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the fiscal year ended June 30, 2015)	Incorporated by Reference
3.2	Amended and Restated Bylaws, effective September 29, 2020 (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed September 29, 2020)	Incorporated by Reference
4.1	Description of Securities (incorporated by reference to Exhibit 4.1 to Annual Report on Form 10-K for the fiscal year ended June 30, 2019)	Incorporated by Reference
10.1	Electromed, Inc. 2012 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed November 15, 2011)*	Incorporated by Reference
10.2	Form of Stock Option Award Agreement under the Electromed, Inc. 2012 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to Quarterly Report on Form 10-Q for the quarter ended December 31, 2011)*	Incorporated by Reference
10.3	Electromed, Inc. 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed November 25, 2014)*	Incorporated by Reference
10.4	Form of Incentive Stock Option Agreement under the Electromed, Inc. 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed November 25, 2014)*	Incorporated by Reference

Exhibit
Number	Description	Method of Filing
10.5	Form of Nonqualified Stock Option Agreement under the Electromed, Inc. 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to Current Report on Form 8-K filed November 25, 2014)*	Incorporated by Reference
10.6	Form of Restricted Stock Agreement under the Electromed, Inc. 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to Current Report on Form 8-K filed November 25, 2014)*	Incorporated by Reference
10.7	Electromed, Inc. 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.1 to Registration Statement on Form S-8 filed December 4, 2017)*	Incorporated by Reference
10.8	Form of Restricted Award Agreement under the 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.11 to Annual Report on Form 10-K for the year ended June 30, 2018)*	Incorporated by Reference
10.9	Form of Non-Qualified Option Agreement under the 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q for the quarter ended March 31, 2019)*	Incorporated by Reference
10.10	Form of Restricted Stock Agreement (Non-Employee Directors) under the 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.13 to Annual Report on Form 10-K for the year ended June 30, 2018)*	Incorporated by Reference
10.11	Non-Competition, Non-Solicitation and Confidentiality Agreement with Kathleen Skarvan dated effective December 1, 2012 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed December 3, 2012)*	Incorporated by Reference
10.12	Amended and Restated Employment Agreement with Kathleen Skarvan dated as of December 2, 2019 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed December 6, 2019)*	Incorporated by Reference
10.13	Employment Agreement with Michael J. MacCourt dated as of May 7, 2020 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed May 18, 2020)*	Incorporated by Reference
10.14	Business Loan Agreement with Choice Financial Group, dated December 18, 2019 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed December 17, 2019)	Incorporated by Reference
10.15	Rider to Business Loan Agreement (Asset Based) with Choice Financial Group, dated December 18, 2019 (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed December 17, 2019)	Incorporated by Reference
10.16	Rider to Business Loan Agreement (Asset Based) with Choice Financial Group, dated December 16, 2020 (incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed December 17, 2020)	Incorporated by Reference
10.17	Description of Fiscal Year 2021 Officer Bonus Plan (incorporated by reference to Exhibit 10.21 to Annual Report on Form 10-K for the fiscal year ended June 30, 2020)*	Incorporated by Reference
10.18	Description of Fiscal Year 2022 Officer Bonus Plan*	Filed Electronically
23.1	Consent of Independent Registered Public Accounting Firm	Filed Electronically
24.1	Powers of Attorney	Filed Electronically
31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically
31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically
32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed Electronically
32.2	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed Electronically
101.CAL	XBRL Taxonomy Extension Calculation Linkbase	Filed Electronically

Period	Total Number of Shares Purchased		Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs
April 1 to April 30, 2021	—		$	—	—		$	—
May 1 to May 30, 2021	—		$	—	—		$	—
June 1 to June 30, 2021		104,211	$	10.79		104,211	$	1,876,000
Total		104,211	$	10.79		104,211	$	1,876,000

	●	Develop and promulgate the body of bronchiectasis clinical evidence to increase physician adoption of the SmartVest System for patients; and
	●	Develop innovative device features in our next generation device that appeal to patients.

	Fiscal Years Ended June 30,
	2021		2020		Increase (Decrease)
Home Care Revenue	$	32,986,000	$	29,323,000	$	3,663,000		12.5	%
Institutional Revenue		1,549,000		2,000,000		(451,000	)	(22.6	%)
Home Care Distributor Revenue		563,000		430,000		133,000		30.9	%
International Revenue		658,000		718,000		(60,000	)	(8.4	%)
Total Revenue	$	35,756,000	$	32,471,000	$	3,285,000		10.1	%

Report of Independent Registered Public Accounting Firm	F-2

Balance Sheets	F-4

Statements of Operations	F-5

Statements of Shareholders’ Equity	F-6

Statements of Cash Flows	F-7

Notes to Financial Statements	F-8

	Years Ended June 30,
	2021			2020
Net revenues	$	35,756,000		$	32,471,000
Cost of revenues		8,451,000			7,271,000
Gross profit		27,305,000			25,200,000

Operating expenses (income)
Selling, general and administrative		22,443,000			19,945,000
Research and development		1,722,000			1,050,000
Government stimulus income		—			(913,000	)
Total operating expenses		24,165,000			20,082,000
Operating income		3,140,000			5,118,000

Interest income, net		39,000			121,000
Other expense, net		(12,000	)		—
Net income before income taxes		3,167,000			5,239,000

Income tax expense		805,000			1,078,000
Net income	$	2,362,000		$	4,161,000

Income per share:
Basic	$	0.28		$	0.50
Diluted	$	0.27		$	0.47

Weighted-average common shares outstanding:
Basic		8,566,224			8,403,220
Diluted		8,911,842			8,826,418

	Common Stock											Total
	Shares		Amount			Additional Paid- in Capital			Retained Earnings			Shareholders’ Equity
Balance as of June 30, 2019	8,408,351		$	84,000		$	16,128,000		$	9,523,000		$	25,735,000
Net income	—			—			—			4,161,000			4,161,000
Issuance of restricted stock	50,000			1,000			(1,000	)		—			—
Issuance of common stock upon exercise of options	109,483			1,000			79,000			—			80,000
Taxes paid on stock option exercised on a net basis	—			—			(628,000	)		—			(628,000	)
Share-based compensation expense	—			—			902,000			—			902,000
Balance as of June 30, 2020	8,567,834			86,000			16,480,000			13,684,000			30,250,000

Net income	—			—			—			2,362,000			2,362,000
Issuance of restricted stock	37,090			—			—			—			—
Issuance of common stock upon exercise of options	32,496			—			46,000			—			46,000
Taxes paid on stock option exercised on a net basis	—			—			(141,000	)		—			(141,000	)
Share-based compensation expense	—			—			1,024,000			—			1,024,000
Repurchase of common stock	(104,211	)		(1,000	)		—			(1,123,000	)		(1,124,000	)
Balance as of June 30, 2021	8,533,209		$	85,000		$	17,409,000		$	14,922,000		$	32,416,000

	June 30, 2021		June 30, 2020
Receivables, included in “Accounts receivable, net of allowance for doubtful accounts”	$	17,032,000	$	12,941,000
Contract assets	$	393,000	$	903,000

	Fiscal Year Ended			Fiscal Year Ended
	June 30, 2021			June 30, 2020
	Increase (decrease)			Increase (decrease)
Contract assets, beginning	$	903,000		$	996,000
Reclassification of contract assets to accounts receivable		(1,551,000	)		(1,858,000	)
Contract assets recognized		1,060,000			1,734,000
Increase (decrease) as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period		(19,000	)		31,000
Contract assets, ending	$	393,000		$	903,000

		ELECTROMED, INC.

Date: August 24, 2021	By	/s/ Kathleen S. Skarvan
		Kathleen S. Skarvan
		President and Chief Executive Officer


Signature	Title	Date

/s/ Kathleen S. Skarvan	President, Chief Executive Officer and Director	August 24, 2021
Kathleen S. Skarvan	(principal executive officer)

/s/ Michael J. MacCourt	Chief Financial Officer	August 24, 2021
Michael J. MacCourt	(principal financial and accounting officer)

*	Chairman and Director	August 24, 2021
Stephen H. Craney

*	Director	August 24, 2021
Stan K. Erickson

*	Director	August 24, 2021
Gregory J. Fluet

*	Director	August 24, 2021
Lee A. Jones

*	Director	August 24, 2021
Andrea M. Walsh

*	Director	August 24, 2021
George H. Winn

	By	/s/ Kathleen S. Skarvan
		Kathleen S. Skarvan
		Attorney-in-Fact

Date:	August 24, 2021	/s/ Kathleen S. Skarvan
		Kathleen S. Skarvan
		President and Chief Executive Officer

Date:	August 24, 2020	/s/ Michael J. MacCourt
		Michael J. MacCourt
		Chief Financial Officer